Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVICTION first-in-human study of ICT01 alone and with pembrolizumab in advanced relapsed or refractory cancers
2024-515560-30-00Phase 2Authorised
- Sponsor
- ImCheck Therapeutics
- Start
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of Ichnocim, pembrolizumab, venetoclax and azacitidine in bladder cancer, breast cancer, colorectal cancer (CRC) and 14 more (4 arms), sponsored by ImCheck Therapeutics. Primary endpoints: Safety and tolerability, Disease control/remission and 1 more. Planned start Mar 2020; status: authorised.
02
Drugs
03
Conditions
bladder cancerbreast cancercolorectal cancer (CRC)gastric cancer (GC)ovarian cancer
Beyond the preview
Go deeper on 2024-515560-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515560-30-00.